Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Emory University
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Fred Hutchinson Cancer Center
Emory University
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
NRG Oncology
NRG Oncology
University of Wisconsin, Madison
OHSU Knight Cancer Institute
NRG Oncology
NRG Oncology
Mayo Clinic
OHSU Knight Cancer Institute
University of Southern California
City of Hope Medical Center
Mayo Clinic
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Mayo Clinic
Jonsson Comprehensive Cancer Center
University of Kansas Medical Center
Mayo Clinic
OHSU Knight Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
University of Southern California
Mayo Clinic
City of Hope Medical Center
Emory University
City of Hope Medical Center
Northwestern University
Northwestern University
OHSU Knight Cancer Institute
University of Rochester
Zhejiang Cancer Hospital
Mayo Clinic
City of Hope Medical Center
Mayo Clinic
Mayo Clinic
Mayo Clinic
Mayo Clinic
City of Hope Medical Center
Zhejiang Cancer Hospital
City of Hope Medical Center
University of Washington